1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Zymeworks Bc Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
Cisplatin (1) · Gemcitabine (1) · Trastuzumab (1) · binimetinib (1) · encorafenib (1) · futibatinib (1) · ivosidenib (1) · neratinib (1) · niraparib (1) · zanidatamab (1)
Belgium (1) · France (1) · United Kingdom (1)
Ivan Borbath, MD (1) · John Bridgewater, MD (1) · Juan W Valle (1) · Julien Edeline, MD (1) · Malka David, MD (1)